Navigation Links
Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity
Date:8/28/2013

y Novel Drug Solutions of Randolph, New Jersey and Dr. Jeffrey T. Liegner of Sparta, New Jersey.  IPI-140 has been successfully administered by Dr. Liegner in more than 1,500 patients in his surgical practice.

Dr. Liegner stated, "The current treatment regimen for the prevention of post-cataract surgery complication is primarily a pre-operative and post-operative self-administered eye drop regimen, which requires from the patient strict compliance and careful adherence to a prescribed dosing schedule. Individuals with physical limitations, impaired manual dexterity, or those who lack of a supportive care giver, are particularly vulnerable to non-compliance and the subsequent complications of untreated post-surgical issues.  This uniquely designed drug, utilizing a fourth generation quinolone therapy combined with potent inflammatory suppression, when placed as a depot inside the vitreous concurrent with cataract surgery, or any intraocular procedure, addresses the primary ocular complications of ophthalmic surgery: infection risk and post-operative inflammation."

Imprimis believes that IPI140 may have broad application in ophthalmic surgery, including the $5 billion global cataract surgery drug market.  According to Ocular Surgery News, the cataract surgery market continues to grow tremendously not only because of the expanding aging population, but because the age at which patients demand cataract surgery has lowered, portending a global market size of $7-$9 billion in the next 5-7 years. 

Imprimis expects to continue to leverage its exclusive relationships with Novel Drug Solutions, Eye Care Northwest, and others to acquire assets with a proven clinical track record.

About Imprimis Pharmaceuticals, Inc.

Imprimis Pharmaceuticals, Inc. (NASDAQ:

SOURCE Imprimis Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
2. Imprimis Pharmaceuticals, Inc. Receives Institutional Review Board (IRB) Approval for its Phase III Clinical Trial Protocol; Phase III Clinical Trial to Begin in 3Q 2013
3. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company
4. Imprimis Pharmaceuticals, Inc. to Present at the National Investment Banking Association (NIBA) Conference June 18th in New York City
5. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
6. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
7. Imprimis Announces Key Leadership Appointments
8. Imprimis Announces Successful Results from its Pharmacokinetic Study for its Impracor Topical NSAID
9. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
10. Imprimis to Begin New Study of Its Topical Analgesic Drug
11. Imprimis Names Two Experts To Its Science And Regulatory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Columbia , May 5, 2015  InMed ... clinical stage biopharmaceutical company that specializes in developing ... former GW Pharmaceuticals financier, investor, and Non-Executive Director, ... InMed as Strategic Advisor with primary responsibility for ... role, Mr. Mountford will leverage his previous success ...
(Date:5/4/2015)... an effort to raise awareness and the need for ... the Health Equity Hero Awards to celebrate the efforts ... than 83 million people in the United ... barriers are most significant for those who experience health ... literacy or geographic isolation.   "Connecting people with ...
(Date:5/4/2015)... Texas, May 4, 2015 Luminex Corporation (NASDAQ: ... ended March 31, 2015. Financial and operating highlights include the ... million, a 2 percent increase over the first quarter of ... a 17 percent increase over the first quarter of 2014. ... the first quarter of 2015.  , GAAP net income ...
Breaking Medicine Technology:InMed Engages Peter Mountford as Strategic Advisor 2InMed Engages Peter Mountford as Strategic Advisor 3InMed Engages Peter Mountford as Strategic Advisor 4DentaQuest Honors Seven Oral Health Leaders As Health Equity Heroes With Inaugural National Award 2DentaQuest Honors Seven Oral Health Leaders As Health Equity Heroes With Inaugural National Award 3DentaQuest Honors Seven Oral Health Leaders As Health Equity Heroes With Inaugural National Award 4Luminex Corporation Reports First Quarter 2015 Results 2Luminex Corporation Reports First Quarter 2015 Results 3Luminex Corporation Reports First Quarter 2015 Results 4Luminex Corporation Reports First Quarter 2015 Results 5Luminex Corporation Reports First Quarter 2015 Results 6Luminex Corporation Reports First Quarter 2015 Results 7Luminex Corporation Reports First Quarter 2015 Results 8Luminex Corporation Reports First Quarter 2015 Results 9Luminex Corporation Reports First Quarter 2015 Results 10Luminex Corporation Reports First Quarter 2015 Results 11
... Resource Expands its Deal... -- OXFORD, England, August 19, 2010 ... ... ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
... MINNEAPOLIS, Aug. 19 Protectus Medical Devices, Inc. ... marketer of innovative medical devices, today named physician/surgeon ... Dr. Hartley has vast experience in research and ... quality control, medical writing and regulatory compliance.  He ...
Cached Medicine Technology:As Pharmaceutical Deal Making Becomes More Competitive, PharmaDeals(R) Resource Expands its Deal Coverage 2As Pharmaceutical Deal Making Becomes More Competitive, PharmaDeals(R) Resource Expands its Deal Coverage 3As Pharmaceutical Deal Making Becomes More Competitive, PharmaDeals(R) Resource Expands its Deal Coverage 4As Pharmaceutical Deal Making Becomes More Competitive, PharmaDeals(R) Resource Expands its Deal Coverage 5As Pharmaceutical Deal Making Becomes More Competitive, PharmaDeals(R) Resource Expands its Deal Coverage 6As Pharmaceutical Deal Making Becomes More Competitive, PharmaDeals(R) Resource Expands its Deal Coverage 7Protectus Medical Devices Appoints as Medical Director a Physician Surgeon With 20-Year Involvement in Senior Level Monitoring of Pharmaceutical and Medical Devices 2Protectus Medical Devices Appoints as Medical Director a Physician Surgeon With 20-Year Involvement in Senior Level Monitoring of Pharmaceutical and Medical Devices 3
(Date:5/4/2015)... 04, 2015 Global Vision, the ... technologies, today announced that it will showcase Proofware ... City Center, in Nashville Tennessee, May 04 and ... first true all-in-one we-based packaging inspection suite, giving ... security of their brand copy and artwork. Proofware ...
(Date:5/4/2015)... 2015 HHT is a rare but ... While it can have seemingly mild symptoms like frequent ... Hereditary Hemorrhagic Telangiectasia (HHT) is a hereditary disorder ... normal capillary connections between an artery and a vein. ... nosebleeds, but may also be present in the lungs, ...
(Date:5/4/2015)... 04, 2015 In a continuing effort ... substance absue, Per Wickstrom, the founder of Choices Recovery ... and the “Salute to the Oscars” celebration held ... the top floor of the luxurious Beverly Hilton Hotel. ... producer of sustainable product placement in TV and film, ...
(Date:5/4/2015)... HERSHEY, Pa. (PRWEB) May 04, 2015 ... M.D. ’87, the 2015 Alumnus of the Year, recognizing ... of excellence and philanthropy he sets for MHS students. ... spark that can happen when children are provided a ... find and hone their passions,” said Pete Gurt ’85, ...
(Date:5/4/2015)... 04, 2015 Each year, the Susan G. ... funds and awareness for breast cancer. This year, Dr. Mark ... featured as the entertainment sponsor for the 25th annual Susan ... 9 at the Lenox Square Mall. , The Komen organization ... to raise $1.2 million. Perimeter Plastic Surgery has not only ...
Breaking Medicine News(10 mins):Health News:Global Vision to Spotlight Proofware at INFO*FLEX 2015 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 3Health News:Per Wickstrom Interviews TV and Film Star Carolyn Hennesy About Substance Abuse and Treatment 2Health News:Milton Hershey School Names 2015 Alumnus of the Year 2Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2
... the efficacy of anticancer vaccines There are ... which are designed to boost the patient,s anticancer immune ... viruses used to deliver the tumor protein to the ... immune system, inducing neutralizing and suppressive responses. But now, ...
... lung cancer (NSCLC), five-year disease-free survival is currently the benchmark ... the follow-up standards: (1) When can cure be declared with ... continued? In order to define a strategy for long-term ... the August edition of the Journal of Thoracic Oncology ...
... studies challenge the controversial hypothesis that venous congestionchronic ... multiple sclerosis (MS). This theory has resulted in ... treatment for MS unproven by clinical trials. The ... negative medical evidence on the subject, are available ...
... today announced that the United States (U.S.) Food and ... botulinum toxin type A for the treatment of adults ... study conducted in Rochester, Minnesota, the prevalence of focal ... at 295 per million people in the U.S. ...
... found that cancer patients from poorer communities have a ... affluent backgrounds even though cancer stage at time of ... in CANCER , a peer-reviewed journal of the ... needed to understand and reduce disparities in the survival ...
... five hospitals in the United States have developed an advanced ... helps radiologists and other physicians extract useful data from a ... manner, according to an article in the August issue of ... ( www.jacr.org ). "Even in its simplest implementation, ...
Cached Medicine News:Health News:JCI online early table of contents: August 2, 2010 2Health News:JCI online early table of contents: August 2, 2010 3Health News:JCI online early table of contents: August 2, 2010 4Health News:JCI online early table of contents: August 2, 2010 5Health News:JCI online early table of contents: August 2, 2010 6Health News:Research defines timeframes, factors to deem early stage lung cancer cured 2Health News:New studies question vascular multiple sclerosis hypothesis and treatment 2Health News:New studies question vascular multiple sclerosis hypothesis and treatment 3Health News:FDA approves Merz Pharmaceuticals' Xeomin (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm 2Health News:FDA approves Merz Pharmaceuticals' Xeomin (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm 3Health News:FDA approves Merz Pharmaceuticals' Xeomin (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm 4Health News:Socioeconomic status predicts survival of Canadian cancer patients 2Health News:Researchers develop advanced search tool to help physician's sort and retrieve vital EMR data 2
... all Gilson disposable pipette tips, ... sterilized version. Each Sterilized TowerPack ... device-quality plastic to help protect ... guaranteed by the red sticker, ...
Designed to fit a variety of 250 L and 300 ul multi-channel pipettors, this tip offers a secure fit and extra space for repeat pipetting....
... Aerosol barrier tips eliminate false ... Scientifically designed and tested, Promega Barrier ... working with amplified nucleic acids (PCR(a)), ... samples, forensic and serological specimens. , ...
Inquire...
Medicine Products: